Century Therapeutics, Inc. filings document a biotechnology issuer developing iPSC-derived cell therapy programs for autoimmune diseases and cancer, along with the formal records supporting its public-company governance and capital structure. Form 8-K reports include operating and financial results, Regulation FD investor-presentation materials, clinical and regulatory program disclosures, and board composition changes.
Proxy and shareholder-vote materials cover annual meeting matters, board and committee governance, and charter-amendment voting, including reverse-stock-split authority. Capital-structure filings include shelf registration and at-the-market equity offering disclosures for common stock, while cover-page disclosures identify Century as an emerging growth company.
Century Therapeutics, Inc. (IPSC) expanded its Board of Directors from six to seven members and appointed Joseph Truitt as a Class I director effective September 9, 2026, with a term running to the 2028 annual stockholders’ meeting. Truitt will also serve on the Compensation Committee and has been deemed an independent director under Nasdaq rules.
For his board service, Truitt will receive an initial option to purchase 148,000 shares of common stock vesting in equal monthly installments over 36 months, plus an annual cash retainer of $40,000, under Century’s existing non‑employee director compensation program. Century highlighted continued progress of its pipeline, stating that CNTY‑813 remains on track for an IND submission in the fourth quarter of 2026 and that CNTY‑308 is anticipated to enter the clinic in 2026, both leveraging its Allo‑Evasion™ 5.0 platform.
Century Therapeutics, Inc. (IPSC) has a notice of proposed sale of common stock under Rule 144 by officer Gregory Russotti. The notice covers the planned sale of 534 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ. The filer also reports prior sales in the last three months, and notes that the transaction includes shares sold to satisfy a tax obligation arising from the settlement of a vested equity award.
Century Therapeutics, Inc. (IPSC) reported an insider tax-related share disposition by President and CEO Brent Pfeiffenberger. On 2026-08-14, 31,172 shares of common stock were withheld by the company at $1.92 per share to satisfy tax withholding obligations upon vesting of restricted stock units. After this withholding, Pfeiffenberger directly holds 3,634,302 shares of Century Therapeutics common stock.
Century Therapeutics, Inc. reported second quarter 2026 results and pipeline updates. The company is advancing CNTY-813, an iPSC-derived cell therapy for type 1 diabetes, having held a pre-IND meeting with the FDA that yielded alignment on its nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design. Phase 1 manufacturing has been established with consistent product quality, and an IND filing for CNTY-813 remains on track for the fourth quarter of 2026. CNTY-308 is planned to enter the clinic in 2026.
For the quarter ended June 30, 2026, Century reported no collaboration revenue, compared with $109.2 million in collaboration revenue in the first half of 2025. The company recorded a net loss of $34.6 million for the quarter and $56.2 million for the first half of 2026, versus net income of $44.0 million in the first half of 2025. Results include an $11.1 million loss on lease component termination. Research and development expenses declined to $19.6 million from $26.9 million in the prior-year quarter, and general and administrative expenses fell to $5.8 million from $7.8 million. As of June 30, 2026, cash and cash equivalents were $49.6 million, with short-term investments of $70.1 million and long-term investments of $77.5 million.
Century Therapeutics reported a larger net loss as collaboration revenue fell away but liquidity strengthened. For the quarter ended June 30, 2026, net loss was $34.6 million (six‑month loss $56.2 million) versus six‑month net income of $44.0 million a year earlier, when $109.2 million of Bristol‑Myers Squibb collaboration revenue was recognized.
Total assets were $287.0 million, including cash, cash equivalents and investments of $197.2 million. A January 2026 private placement raised about $126.4 million, increasing shares outstanding to 180.5 million. Management expects existing cash resources to fund operations into the first quarter of 2029.
Research and development and general and administrative expenses declined year over year, but results included an $11.1 million loss on a Philadelphia lease component termination. The company derecognized $3.8 million of contingent consideration after milestones expired and continues IND‑enabling work on lead programs CNTY‑813 and CNTY‑308.
Century Therapeutics, Inc. senior vice president of Finance & Operations Douglas Carr reported selling 275 shares of common stock on August 3, 2026 at $1.977 per share. According to the footnote, these shares were sold automatically to cover tax withholding obligations from vesting restricted stock units, and were not sold at his discretion. Following the sale, Carr directly held 504819 shares of common stock.
Century Therapeutics, Inc. updated the employment terms for its Chief Scientific Officer, Chad Cowan, Ph.D., through an Amended and Restated Employment Agreement. Under this new arrangement, he will continue serving as Chief Scientific Officer on a part-time basis with a reduced annual salary of $296,150.
Dr. Cowan will remain eligible for an annual performance-based target bonus, calculated on a pro-rated basis to reflect his part-time role. If his employment ends through termination by the company or his resignation, he will receive all accrued and unpaid base salary through his final date of employment.
Century Therapeutics, Inc. executive Gregory Russotti reported an automatic sale of shares to cover taxes on vested stock awards. On June 12, 2026, 2,584 shares of common stock were sold in open-market transactions at an average price of $2.232 per share to satisfy tax withholding obligations tied to restricted stock unit vesting. The filing explains these sales were automatic and not at Russotti’s discretion. After the sale, he directly held 512,319 common shares and indirectly held 92,773 shares through the Gregory Russotti 2021 Family Trust.
Century Therapeutics, Inc. senior vice president of finance and operations Douglas Carr reported an automatic sale of common stock tied to tax withholding. On June 12, 2026, he sold 1,654 shares at $2.232 per share in an open-market transaction to cover taxes from restricted stock unit vesting.
These sales were executed automatically and not at his discretion, according to the disclosure. After the transaction, Carr still directly owns 505,094 shares of Century Therapeutics common stock, indicating he retains a substantial equity position in the company.
Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 13,849 shares of Common Stock at $2.24 per share to satisfy tax withholding obligations. This was not an open-market sale, and Pfeiffenberger continues to hold 3,665,474 shares of Common Stock directly after the transaction.